| Autor: |
Serpico AF; CEINGE Biotecnologie Avanzate, 80145 Naples, Italy. angelaflavia.serpico@hotmail.it.; DMMBM, University of Naples 'Federico II', 80131 Naples, Italy. angelaflavia.serpico@hotmail.it., D'Alterio G; CEINGE Biotecnologie Avanzate, 80145 Naples, Italy. giusdalt95@gmail.com.; DMMBM, University of Naples 'Federico II', 80131 Naples, Italy. giusdalt95@gmail.com., Vetrei C; CEINGE Biotecnologie Avanzate, 80145 Naples, Italy. c.vetrei@studenti.unina.it.; DMMBM, University of Naples 'Federico II', 80131 Naples, Italy. c.vetrei@studenti.unina.it., Della Monica R; CEINGE Biotecnologie Avanzate, 80145 Naples, Italy. rosa_d@hotmail.it., Nardella L; CEINGE Biotecnologie Avanzate, 80145 Naples, Italy. lucanardella95@gmail.com.; DMMBM, University of Naples 'Federico II', 80131 Naples, Italy. lucanardella95@gmail.com., Visconti R; IEOS, CNR, 80131 Naples, Italy. visconti@unina.it., Grieco D; CEINGE Biotecnologie Avanzate, 80145 Naples, Italy. domenico.grieco@unina.it.; Department of Pharmacy, University of Naples 'Federico II', 80131 Naples, Italy. domenico.grieco@unina.it. |
| Abstrakt: |
Wee1 kinase is an inhibitor of cyclin-dependent kinase (cdk)s, crucial cell cycle progression drivers. By phosphorylating cdk1 at tyrosine 15, Wee1 inhibits activation of cyclin B-cdk1 (Cdk1), preventing cells from entering mitosis with incompletely replicated or damaged DNA. Thus, inhibiting Wee1, alone or in combination with DNA damaging agents, can kill cancer cells by mitotic catastrophe, a tumor suppressive response that follows mitosis onset in the presence of under-replicated or damaged DNA. AZD1775, an orally available Wee1 inhibitor, has entered clinical trials for cancer treatment following this strategy, with promising results. Recently, however, AZD1775 has been shown to inhibit also the polo-like kinase homolog Plk1 in vitro, casting doubts on its mechanism of action. Here we asked whether, in the clinically relevant concentration range, AZD1775 inhibited Wee1 or Plk1 in transformed and non-transformed human cells. We found that in the clinically relevant, nanomolar, concentration range AZD1775 inhibited Wee1 rather than Plk1. In addition, AZD1775 treatment accelerated mitosis onset overriding the DNA replication checkpoint and hastened Plk1-dependent phosphorylation. On the contrary selective Plk1 inhibition exerted opposite effects. Thus, at therapeutic concentrations, AZD1775 inhibited Wee1 rather than Plk1. This information will help to better interpret results obtained by using AZD1775 both in the clinical and experimental settings and provide a stronger rationale for combination therapies. |
